Can-Fite Biopharma shares surge 10.64% premarket after successful liver transplant case linked to Namodenoson.

Can-Fite Biopharma (NYSE American: CANF) surged 10.64% in premarket trading following the announcement that its drug Namodenoson contributed to the successful liver transplantation of a patient with advanced decompensated liver cirrhosis. The patient, treated under a compassionate use framework, achieved clinical stabilization, maintaining transplant eligibility until a donor organ became available. Prof. Ohad Etzion, a liver disease specialist, highlighted the significance of this outcome for fragile patient populations. Namodenoson is currently in pivotal Phase III trials for advanced liver cancer and Phase IIb trials for MASH, underscoring its therapeutic potential. The positive case report, coupled with the drug’s ongoing clinical development, likely drove investor optimism despite the company’s broader financial challenges.